The total number of retail stores has exceeded 10,000!

A few days ago, Sinopharm Holdings released its 2021 annual results, achieving business income of 521.
051 billion yuan, a year-on-year increase of 14.
16%, and a continuous increase in growth compared with 2020; net profit attributable to the parent reached 7.
759 billion yuan, a year-on-year increase of 7.
95%
.
Retail business revenue exceeds 29 billion The financial report shows that Sinopharm has three major business sectors: pharmaceutical distribution, medical equipment and pharmaceutical retail
.
Among them, the pharmaceutical retail business income was 29.
059 billion yuan, a year-on-year increase of 20.
26%, much higher than the industry average growth level
.
The proportion of retail business revenue reached 5.
41%, an increase of 0.
26 percentage points year-on-year
.
In 2021, Sinopharm Holding will give full play to the business advantages of professional pharmacies and traditional pharmacies.
While continuously improving the network layout of retail pharmacies, it will focus on expanding the pharmacy stores with "medical insurance co-ordination pharmacy" and "dual-channel" qualifications, so as to improve the retail store's capacity.
Professional pharmacy and marketing service capabilities
.
As of the end of 2021, the total number of retail stores of Sinopharm Holdings reached 10,259, an increase of 1,282 from the end of the previous year.
Among them, there were 8,798 Guoda pharmacies, an increase of 1,138 from the end of the previous year; and 1,461 professional pharmacies, an increase of 144 from the end of the previous year
.
In 2021, the "dual-channel" policy promulgated by the state and the policies of "special chronic disease designated retail pharmacies enjoying comprehensive medical insurance payment treatment" have been successively introduced, which will open up the availability of prescription drugs, especially outpatient special diseases and outpatient chronic disease drugs at the retail end.
The demand for medicines brings growth space for the retail industry
.
According to the data, in the first three quarters of 2021, the sales of the pharmaceutical retail market reached RMB 399 billion, a year-on-year increase of 8.
33% and an increase of 14.
98% from the same period in 2019
.
As of the end of 2021, the total number of "dual-channel" pharmacies of Sinopharm Holdings has reached 403, covering 25 provinces across the country
.
In addition, in the pharmaceutical distribution sector, Sinopharm Holding firmly grasped the industry transformation trend brought about by volume procurement, and promoted the transformation of pharmaceutical circulation to a national and intensive service by continuously exploiting the scale advantages of the distribution network.

.
As of the end of 2021, the revenue from the drug distribution business was 389.
955 billion yuan, a year-on-year increase of 11.
96%
.
Among them, the grass-roots market business continued to expand, and the terminal network in various provinces (autonomous regions and municipalities) covered more than 500,000
.
In the medical device sector, Sinopharm has continued to develop rapidly, achieving a net growth of approximately RMB 20 billion for two consecutive years
.
In 2021, the sales revenue will be 108.
129 billion yuan, accounting for 20.
14% from 19.
04% in the previous year
.
At the same time, Sinopharm's medical device business network covers 335 prefecture-level cities and above, and the scale of direct sales to medical terminals exceeds 100 billion yuan, and its market share continues to rank among the forefront of the medical device circulation industry
.
On October 28, 2021, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-Quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period", proposing that "by 2025, 5-10 companies with more than 500 companies will be formed.
The annual sales of the top 100 pharmaceutical retail companies account for more than 65% of the total pharmaceutical retail market; the drug retail chain rate is close to 70%
.
" This policy guidance document laid the foundation for China's pharmaceutical industry.
The main tone for the development of the retail industry in the next five years: increasing scale, improving level, specialization, diversification, and high-quality development
.
At present, among the top ten chain pharmacies in the country, the “aircraft carrier” of the most promising pharmacy with a scale of over 50 billion is the Guoda Pharmacy that ranks first
.
As a 50 billion seed player, what weapons and skills does Guoda Pharmacy possess? We can get a glimpse of this from the 2021 semi-annual report of Sinopharm Accord
.
In the semi-annual report, Sinopharm consistently used "new high" and "highest in recent years" to describe the speed of Guoda Pharmacy's store expansion
.
In the first half of 2021, Guoda Pharmacy opened 788 new stores, closed 223 stores, a net increase of 565 stores, and opened a new high; among them, 632 newly opened direct-sale stores achieved sales of 117 million yuan, of which, the newly opened hospital side 48 stores, the most in recent years
.
Taking full advantage of State-controlled resources, Guoda Pharmacy actively promotes the implementation of investment and M&A projects
.
In the first half of 2021, new investment projects will be consolidated into 257 stores; actively source new projects and accelerate the implementation of intended investment projects
.
Clearly, accelerating the pace and scale of M&A in 2022 will remain the main driver of Guoda's growth
.
In addition to store expansion, DTP Pharmacy and O2O have also brought considerable growth to Guoda Pharmacy
.
With the help of O2O expansion, Guoda Pharmacy accelerated its omni-channel penetration and promoted transformation and upgrading with innovative business
.
In the first half of the year, O2O achieved sales of 255 million, a year-on-year increase of 122%
.
Direct DTP revenue was 1.
305 billion, a year-on-year increase of 34%
.
As Sinopharm said, the implementation of the "dual channel" policy will bring huge development opportunities to the retail business
.
In the "transcript", Sinopharm stated that it will accelerate the expansion of "dual-channel" and "medical insurance co-ordination pharmacies" with strong professional pharmacy service capabilities, and undertake opportunities for outflow of prescription drugs
.
At the same time, in the face of technological upgrades and iterations of physical business formats, Sinopharm Holding will accelerate the application of innovative technologies such as AI-assisted consulting and online service capabilities, improve the professional pharmaceutical service level of pharmacies, explore multi-channel retail business scenarios, and optimize terminals.
Service capabilities, promote the synergistic growth of online platforms and offline physical businesses, and actively meet the needs of grass-roots communities for chronic, serious and special diseases
.